SABR associated with higher three-year mortality than surgery in early-stage NSCLC
Among 12,546 patients with early-stage NSCLC, adjusted three-year mortality was 30.3% after SABR versus 21.6% after surgery.
Among 12,546 patients with early-stage NSCLC, adjusted three-year mortality was 30.3% after SABR versus 21.6% after surgery.
In 378 prostate SABR patients, rectal spacer use was associated with lower one-year grade ≥1 gastrointestinal toxicity after adjustment (OR 0.31).
A retrocrural nodal lesion regressed after 42 Gy in three fractions, with AFP normalization and no radiological disease at 15 months.
In a 21-patient phase II cohort, one-year recurrence-free survival was 71.4% after neoadjuvant SABR and thrombectomy, with no 90-day mortality.
MR-only prostate SABR reduced median penile bulb dose from 4.6 to 2.2 Gy, with lower observed urinary and sexual toxicity in nonrandomized cohorts.
In 778 patients, single-fraction SABR showed similar local failure, survival and toxicity to three- or four-fraction treatment.
Adaptation preserved prescription-level D99 in all 50 fractions, while a 1-mm margin achieved 98% despite minimal daily dose perturbation.
SABR achieved 92.5% one-year local control in oligometastatic breast cancer, while pooled randomized evidence did not definitively establish a PFS benefit.
In ARGOS-CLIMBER, PSMA/MRI-guided five-fraction pelvic SABR produced a 67% PET complete response rate at two years with limited late GU toxicity.
Quality of life remained stable after 30–37.5 Gy in three fractions, while symptomatic patients achieved 59% pain response at 24 weeks.
Accumulated gastrointestinal doses were generally lower than planned, while higher small-bowel dose showed exploratory associations with diarrhoea after MR-guided SABR.
Daily surface changes shifted proton beam depth by up to 17.4 mm and reduced accumulated target D99 by up to 24.3%.
Combining ISUP grade with 3–6-month PSA-density kinetics separated seven-year biochemical control at 93.5% versus 53.4% after SABR without ADT.
Five weekly SABR fractions to prostate and pelvic nodes produced 10.5% five-year biochemical failure with low persistent gastrointestinal and urinary toxicity.
In 2024, only 3.2% of English patients began curative radiotherapy within the 49-day target despite rapidly rising demand.